RxDoctor Payments Data

Steven Ching, MD

Internal Medicine · Hemet, CANPI 1770016081

Payments from drug & device makers

$2,737in general payments, 2019–2025

Across 133 payments — averaging $20.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$641
  • Medtronic$202
  • Merck$191
  • Amgen$175
  • GSK$167
  • Abbott$167
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$1295%
  • Food & beverage$2,60895%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,737 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$69,931
Medicare patients
236
Services billed
5,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$213,174
OzempicSemaglutide87$115,090
JardianceEmpagliflozin60$73,092
XareltoRivaroxaban50$62,909
JanuviaSitagliptin Phosphate48$60,376
RybelsusSemaglutide20$39,874
EntrestoSacubitril/Valsartan24$32,783
FarxigaDapagliflozin Propanediol32$29,573
Repatha SureclickEvolocumab20$18,382
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$16,919
Spiriva RespimatTiotropium Bromide23$12,890
Atorvastatin Calcium1,192$12,143
Breo ElliptaFluticasone/Vilanterol25$11,683
Tresiba Flextouch U-100Insulin Degludec26$11,344
Gabapentin387$10,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$213,174202 claims
Novo NordiskOzempic, Rybelsus$641$154,965107 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat$80$92,65798 claims
Johnson & JohnsonXarelto$81$62,90950 claims
MerckJanuvia$191$60,37648 claims
NovartisEntresto$67$32,78324 claims
AstraZenecaFarxiga$157$29,57332 claims
GSKTrelegy Ellipta, Breo Ellipta$167$28,60245 claims
Lilly USA, LLCHumulin N, Humalog$23$7,93834 claims
AbbVieSynthroid$107$3,53186 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hemet

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →